• Aliases: MoAb CD52, anti-CD52 monoclonal antibody, humanized IgG1 anti-CD52 monoclonal antibody
    • As of September 4, 2012, alemtuzumab (Campath) is no longer commercially available in the United States (or Europe).
    • Campath remains accessible (free of charge) through the Campath Distribution Program for the treatment of B-cell CLL and select unlabeled uses.
    • In February 2014, alemtuzumab was launched under a different trade name of Lemtrada for use in multiple sclerosis with lower doses.
    • Recommended dose: 3 mg IV on day 1; if no reaction, increase to 10 mg IV on day 3; again increase to full dose 30 mg IV TIW for a total of 12 doses
    Other topics in Targeted and Immunotherapy Agents